AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25243084 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 98
Study 21546942 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented feeding (Lactobacillus rhamnosus GG and Bifidobacterium infantis added to enteral feeding, continued once daily until discharge or 34 weeks PMA)
Number of subjects: 101
Study 21546942 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic-supplemented feeding
Number of subjects: 101
Study 21546942 — intervention group
Group type: COMPARATOR
Intervention: Control group (unsupplemented feedings)
Number of subjects: 101
Study 21546942 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 20423755 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral high-dose dexamethasone
Number of subjects: 62
Study 20423755 — intervention group
Group type: COMPARATOR
Intervention: Daily high-dose prednisolone
Number of subjects: 62
Study 18922117 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by hormonal therapy
Number of subjects: 4500
Study 18922117 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 4500
Study 15797962 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) and luteinizing hormone releasing hormone analog (LHRHa)
Number of subjects: 14
Study 12206636 — intervention group
Group type: EXPERIMENTAL
Intervention: Various dose fractionation schedules for breast cancer radiotherapy
Number of subjects: 56
Study 12206636 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality assurance programme for the START Trial
Number of subjects: 56
Study 12206636 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to the trial protocol
Number of subjects: 56
Study 12412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 0.5 mg
Number of subjects: 30
Study 12412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 1 mg
Number of subjects: 30
Study 12412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 2.5 mg
Number of subjects: 30
Study 12412823 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan nasal spray 5 mg
Number of subjects: 30
Study 12412823 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg)
Number of subjects: 30
Study 10214642 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitions practice group
Number of subjects: 54
Study 10214642 — intervention group
Group type: EXPERIMENTAL
Intervention: Random practice group
Number of subjects: 54
Study 10214642 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined practice group
Number of subjects: 54
Study 8594954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl, sodium thiopental, succinylcholine 1 mg/kg
Number of subjects: 100
Study 8594954 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg fentanyl and propofol (demand-adapted)
Number of subjects: 100
Study 8594954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg fentanyl and propofol (demand-adapted)
Number of subjects: 100
Study 8594954 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg fentanyl, propofol, succinylcholine 1 mg/kg
Number of subjects: 100
Study 8594954 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium thiopental/succinylcholine
Number of subjects: 100
Study 2538051 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat rolls with bran labeled with 55Fe and 59Fe
Number of subjects: 0
Study 2538051 — intervention group
Group type: COMPARATOR
Intervention: Wheat rolls without bran labeled with 55Fe and 59Fe
Number of subjects: 0
Study 455774 — intervention group
Group type: EXPERIMENTAL
Intervention: Grommet insertion
Number of subjects: 91
Study 455774 — intervention group
Group type: COMPARATOR
Intervention: Intact ear (control)
Number of subjects: 91
Study 455774 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ears (operated and intact)
Number of subjects: 91
Study 30824401 — intervention group
Group type: EXPERIMENTAL
Intervention: Active yogurt with lipid emulsions encapsulated in calcium-alginate beads
Number of subjects: 33
Study 30824401 — intervention group
Group type: COMPARATOR
Intervention: Control yogurt containing nonencapsulated nutrients
Number of subjects: 33
Study 28182457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 171
Study 28182457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Number of subjects: 171
Study 28182457 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Number of subjects: 171
Study 26299229 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide treatment
Number of subjects: 4379
Study 26299229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic response (weight loss per 40 mg of furosemide)
Number of subjects: 4379
Study 26299229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic response (good responders)
Number of subjects: 4379
Study 26299229 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic response based on urine output per 40 mg of furosemide
Number of subjects: 4379
Study 23708881 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritonsillar infiltration with dexamethasone and levobupivacaine (Group A)
Number of subjects: 120
Study 23708881 — intervention group
Group type: COMPARATOR
Intervention: i.v. dexamethasone and peritonsillar levobupivacaine infiltration (Group B)
Number of subjects: 120
Study 22506436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive zonisamide
Number of subjects: 104
Study 22506436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 20192134 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing ankle weights
Number of subjects: 0
Study 20192134 — intervention group
Group type: COMPARATOR
Intervention: Not wearing ankle weights
Number of subjects: 0
Study 17911992 — intervention group
Group type: EXPERIMENTAL
Intervention: Retapamulin ointment, 1% (twice daily for 5 days)
Number of subjects: 519
Study 17911992 — intervention group
Group type: COMPARATOR
Intervention: Sodium fusidate ointment, 2% (3 times daily for 7 days)
Number of subjects: 519
Study 15258018 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple procedure with core vitrectomy
Number of subjects: 31
Study 15258018 — intervention group
Group type: COMPARATOR
Intervention: Control group (triple procedure without vitrectomy)
Number of subjects: 31
Study 11502915 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 21
Study 11502915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9084888 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal suppository containing ozagrel tablet
Number of subjects: 6
Study 9084888 — intervention group
Group type: COMPARATOR
Intervention: Oral ozagrel tablet
Number of subjects: 6
Study 8125395 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 0
Study 8125395 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutritional support in conjunction with radiotherapy or chemotherapy
Number of subjects: 0
Study 3234516 — intervention group
Group type: EXPERIMENTAL
Intervention: Turbuhaler (multiple dose powder inhaler)
Number of subjects: 12
Study 3234516 — intervention group
Group type: COMPARATOR
Intervention: Pressurized inhaler
Number of subjects: 12
Study 29315168 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training regimen of 72 supervised treadmill walking sessions delivered thrice weekly for 24 consecutive weeks
Number of subjects: 25
Study 26161932 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function tests (30-s chair stand test)
Number of subjects: 185
Study 26161932 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task performance (counting backwards)
Number of subjects: 185
Study 24767299 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified chitosan
Number of subjects: 250
Study 24767299 — intervention group
Group type: COMPARATOR
Intervention: Control (no adhesive prevention substance)
Number of subjects: 250
Study 22375971 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 309
Study 22375971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 20070921 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-age peer tutoring (PR)
Number of subjects: 260
Study 20070921 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-age peer tutoring (PR)
Number of subjects: 260
Study 20070921 — intervention group
Group type: COMPARATOR
Intervention: Control group (no peer tutoring)
Number of subjects: 260
Study 19114389 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA supplements and low n-6 PUFA cooking oils and spreads
Number of subjects: 0
Study 19114389 — intervention group
Group type: COMPARATOR
Intervention: Control intervention designed to maintain usual fatty acid intake
Number of subjects: 0
Study 15855365 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous chondrocyte implantation with collagen cover (ACI-C)
Number of subjects: 91
Study 15855365 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix-induced autologous chondrocyte implantation (MACI)
Number of subjects: 91
Study 15050086 — intervention group
Group type: EXPERIMENTAL
Intervention: NADA‐Acudetox protocol
Number of subjects: 163
Study 15050086 — intervention group
Group type: COMPARATOR
Intervention: Helix control protocol
Number of subjects: 163
Study 15050086 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NADA and Helix)
Number of subjects: 163
Study 10978947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based treatment (colloidal bismuth subcitrate 120 mg qid plus metronidazole 250 mg qid plus tetracycline 500 mg qid)
Number of subjects: 111
Study 10978947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 10978947 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth-based treatment
Number of subjects: 111
Study 8614419 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (n = 696)
Number of subjects: 1094
Study 8614419 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 398)
Number of subjects: 1094
Study 1442450 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen (1 mg, 2x/day)
Number of subjects: 16
Study 1442450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 3925863 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cefoxitin
Number of subjects: 0
Study 3925863 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3027267 — intervention group
Group type: COMPARATOR
Intervention: ad lib nutritional intake (control group)
Number of subjects: 192
Study 3027267 — intervention group
Group type: EXPERIMENTAL
Intervention: specific nutritional intervention (standard group)
Number of subjects: 192
Study 3027267 — intervention group
Group type: EXPERIMENTAL
Intervention: augmented group
Number of subjects: 192
Study 3027267 — intervention group
Group type: EXPERIMENTAL
Intervention: nutritional interventions using dietary counselling
Number of subjects: 192
Study 3027267 — intervention group
Group type: EXPERIMENTAL
Intervention: multivariate prognostic factor analysis for lung cancer
Number of subjects: 192
Study 3027267 — intervention group
Group type: EXPERIMENTAL
Intervention: multivariate prognostic factor analysis for colorectal cancer
Number of subjects: 192
Study 31455174 — intervention group
Group type: EXPERIMENTAL
Intervention: L2 immersion program with L1 use prohibited for seven weeks
Number of subjects: 0
Study 31602573 — intervention group
Group type: EXPERIMENTAL
Intervention: AG200‐15 patch (N=78)
Number of subjects: 83
Study 31602573 — intervention group
Group type: COMPARATOR
Intervention: Xulane patch (N=77)
Number of subjects: 83
Study 28949010 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral micronized progesterone, six-hourly, starting at 14-18 weeks until 37 weeks or delivery
Number of subjects: 212
Study 26403840 — intervention group
Group type: EXPERIMENTAL
Intervention: Rights-based sexuality education curriculum
Number of subjects: 1447
Study 26403840 — intervention group
Group type: COMPARATOR
Intervention: Basic sex education (control) curriculum
Number of subjects: 1447
Study 24579221 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 100
Study 24579221 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA)
Number of subjects: 100
Study 22024310 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg oral on day 1, 10 mg/day oral on days 2-4) with palonosetron (0.25 mg IV) and dexamethasone (20 mg IV)
Number of subjects: 241
Study 22024310 — intervention group
Group type: COMPARATOR
Intervention: Aprepitant (125 mg oral on day 1, 80 mg oral on days 2-3) with palonosetron (0.25 mg IV) and dexamethasone (12 mg IV)
Number of subjects: 241
Study 18087165 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 67
Study 18087165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 16426697 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day
Number of subjects: 200
Study 16426697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 11886025 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (CBT), 16 sessions
Number of subjects: 88
Study 11886025 — intervention group
Group type: COMPARATOR
Intervention: Usual HMO care
Number of subjects: 88
Study 9457343 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 40
Study 9457343 — intervention group
Group type: COMPARATOR
Intervention: Unresurfaced patella
Number of subjects: 40
Study 7616988 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg zidovudine immediately
Number of subjects: 1637
Study 7616988 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg zidovudine immediately
Number of subjects: 1637
Study 7616988 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy (placebo until CD4 < 500)
Number of subjects: 1637
Study 2092283 — intervention group
Group type: EXPERIMENTAL
Intervention: MivP
Number of subjects: 277
Study 2092283 — intervention group
Group type: COMPARATOR
Intervention: VBAMDex
Number of subjects: 277
Study 2092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifn‐alpha maintenance
Number of subjects: 277
Study 2092283 — intervention group
Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 277
Study 2092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II patients
Number of subjects: 277
Study 2092283 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage III patients
Number of subjects: 277
Study 31530662 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time continuous glucose monitoring (rtCGM)
Number of subjects: 0
Study 31530662 — intervention group
Group type: COMPARATOR
Intervention: Self-monitored blood glucose (SMBG)
Number of subjects: 0
Study 29766772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg daily)
Number of subjects: 7213
Study 29766772 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg daily)
Number of subjects: 7213
Study 27445354 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for psychiatrists (four group and one individualised session)
Number of subjects: 97
Study 27445354 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication training for psychiatrists
Number of subjects: 97
Study 24987193 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 30
Study 24987193 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electric stimulation (NMES)
Number of subjects: 30
Study 24987193 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion (CWI)
Number of subjects: 30
Study 22222514 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet needs for social support
Number of subjects: 83
Study 22222514 — intervention group
Group type: COMPARATOR
Intervention: Social support received
Number of subjects: 83
Study 20823124 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital-delivered multifactorial falls prevention programme
Number of subjects: 364
Study 20823124 — intervention group
Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 364
Study 18620849 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intra-nasal midazolam
Number of subjects: 65
Study 18620849 — intervention group
Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 65
Study 16828858 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-session one-on-one school nurse-delivered smoking cessation intervention
Number of subjects: 1148
Study 14765721 — intervention group
Group type: EXPERIMENTAL
Intervention: Bibliotherapy plus telephone contact weight‐loss program
Number of subjects: 43
Study 14765721 — intervention group
Group type: COMPARATOR
Intervention: Bibliotherapy weight‐loss program
Number of subjects: 43
Study 10473085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicine, and etoposide
Number of subjects: 93
Study 10473085 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, epirubicine and vincristine alternating with carboplatin and etoposide
Number of subjects: 93
Study 10473085 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 93
Study 8897751 — intervention group
Group type: EXPERIMENTAL
Intervention: Water fluoridation at 0.7 ppm fluoride using sodium silicofluoride
Number of subjects: 0
Study 1941407 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk fortified with human milk protein (HMP)
Number of subjects: 21
Study 1941407 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine milk protein preparation (BMP)
Number of subjects: 21
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG foci on the left side
Number of subjects: 2543
Study 7212987 — intervention group
Group type: COMPARATOR
Intervention: EEG foci on the right side
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal region foci
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital region foci
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta foci
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: All diagnoses
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG examiners
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha waves, focal dysrhythmias, theta wave foci
Number of subjects: 2543
Study 7212987 — intervention group
Group type: EXPERIMENTAL
Intervention: General left preponderance of EEG foci
Number of subjects: 2543
Study 30535871 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 100
Study 30535871 — intervention group
Group type: COMPARATOR
Intervention: Pioglitazone
Number of subjects: 100
Study 29030697 — intervention group
Group type: EXPERIMENTAL
Intervention: Geomagnetic storm (S) exposure
Number of subjects: 0
Study 29030697 — intervention group
Group type: COMPARATOR
Intervention: Quiet (Q) exposure
Number of subjects: 0
Study 29933530 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine comprehensive therapy
Number of subjects: 51
Study 29933530 — intervention group
Group type: COMPARATOR
Intervention: Modern Western Medicine treatment
Number of subjects: 51
Study 22612425 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling protocol (20‐min water immersion, 15 °C)
Number of subjects: 9
Study 22612425 — intervention group
Group type: COMPARATOR
Intervention: Noncooling protocol
Number of subjects: 9
Study 22341998 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 145
Study 20381870 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous risk genotype for rs10490924 in LOC387715/ARMS2
Number of subjects: 114
Study 20381870 — intervention group
Group type: COMPARATOR
Intervention: Homozygous nonrisk genotype for rs10490924 in LOC387715/ARMS2
Number of subjects: 114
Study 20381870 — intervention group
Group type: COMPARATOR
Intervention: Other genetic variants (CFH, C2, C3, APOE, TLR3)
Number of subjects: 114
Study 20381870 — intervention group
Group type: COMPARATOR
Intervention: Progression to central GA from extrafoveal GA and development of bilateral GA
Number of subjects: 114
Study 18532895 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 12
Study 18532895 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (Control)
Number of subjects: 12
Study 15798915 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine diluted 1:100 mouthwashes
Number of subjects: 132
Study 15798915 — intervention group
Group type: COMPARATOR
Intervention: Normal saline mouthwashes
Number of subjects: 132
Study 12461401 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive intervention
Number of subjects: 6179
Study 12461401 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive intervention
Number of subjects: 6179
Study 12461401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 6179
Study 10757273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg)
Number of subjects: 84
Study 10757273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (50,000 IU)
Number of subjects: 84
Study 10757273 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg)
Number of subjects: 84
Study 10757273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 9023788 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (300 mg/day)
Number of subjects: 42
Study 9023788 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (200 mg/day)
Number of subjects: 42
Study 1890934 — intervention group
Group type: EXPERIMENTAL
Intervention: Purified sulfur (0.5-1 g mixed with 0.25 g of glucose, administered every 2-3 hours before irradiation)
Number of subjects: 34
Study 1890934 — intervention group
Group type: COMPARATOR
Intervention: Placebo (a mixture of egg powder with glucose)
Number of subjects: 34
Study 1890934 — intervention group
Group type: COMPARATOR
Intervention: No protective means used (21 patients)
Number of subjects: 34
Study 6410897 — intervention group
Group type: EXPERIMENTAL
Intervention: Acidophilus milk (240 ml, three times a day for 2 weeks)
Number of subjects: 79